| Year |
Citation |
Score |
| 2023 |
Alenezi WM, Fierheller CT, Serruya C, Revil T, Oros KK, Subramanian DN, Bruce J, Spiegelman D, Pugh T, Campbell IG, Mes-Masson AM, Provencher D, Foulkes WD, Haffaf ZE, Rouleau G, ... ... Tonin PN, et al. Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases. Frontiers in Oncology. 13: 1111191. PMID 36969007 DOI: 10.3389/fonc.2023.1111191 |
0.302 |
|
| 2023 |
Fierheller CT, Alenezi WM, Serruya C, Revil T, Amuzu S, Bedard K, Subramanian DN, Fewings E, Bruce JP, Prokopec S, Bouchard L, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, ... ... Tonin PN, et al. Molecular Genetic Characteristics of , a Proposed New Ovarian Cancer Predisposing Gene. Genes. 14. PMID 36833203 DOI: 10.3390/genes14020277 |
0.362 |
|
| 2021 |
Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, Bedard K, Arcand SL, Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, ... ... Tonin PN, et al. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. Genome Medicine. 13: 186. PMID 34861889 DOI: 10.1186/s13073-021-00998-5 |
0.343 |
|
| 2021 |
Matis TS, Zayed N, Labraki B, de Ladurantaye M, Matis TA, Camacho Valenzuela J, Hamel N, Atayan A, Rivera B, Tabach Y, Tonin PN, Orthwein A, Mes-Masson AM, El Haffaf Z, Foulkes WD, et al. Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families. Npj Breast Cancer. 7: 109. PMID 34433815 DOI: 10.1038/s41523-021-00315-8 |
0.335 |
|
| 2021 |
Fierheller CT, Alenezi WM, Tonin PN. The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families. Cancers. 13. PMID 34298626 DOI: 10.3390/cancers13143406 |
0.386 |
|
| 2021 |
Amuzu S, Carmona E, Mes-Masson AM, Greenwood CMT, Tonin PN, Ragoussis J. Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines. Cancers. 13. PMID 33803939 DOI: 10.3390/cancers13061296 |
0.393 |
|
| 2021 |
Elkholi IE, Di Iorio M, Fahiminiya S, Arcand SL, Han H, Nogué C, Behl S, Hamel N, Giroux S, de Ladurantaye M, Aleynikova O, Gotlieb WH, Côté JF, Rousseau F, Tonin PN, et al. Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer. Scientific Reports. 11: 2409. PMID 33510186 DOI: 10.1038/s41598-021-81106-w |
0.39 |
|
| 2020 |
Felicio PS, Grasel RS, Campacci N, de Paula AE, Galvão HCR, Torrezan GT, Sabato CS, Fernandes GC, Souza CP, Michelli RD, Andrade CE, Barros BDF, Matsushita MM, Revil T, Ragoussis J, ... ... Tonin PN, et al. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer. Human Mutation. PMID 33326660 DOI: 10.1002/humu.24158 |
0.423 |
|
| 2020 |
Le Page C, Amuzu S, Rahimi K, Gotlieb W, Ragoussis J, Tonin PN. LESSONS LEARNED FROM UNDERSTANDING CHEMOTHERAPY RESISTANCE IN EPITHELIAL TUBO-OVARIAN CARCINOMA FROM BRCA1 AND BRCA2 MUTATION CARRIERS. Seminars in Cancer Biology. PMID 32827632 DOI: 10.1016/J.Semcancer.2020.08.005 |
0.433 |
|
| 2020 |
Alenezi WM, Fierheller CT, Recio N, Tonin PN. Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers. Genes. 11: 856. PMID 32726901 DOI: 10.3390/Genes11080856 |
0.496 |
|
| 2019 |
Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Tommasi S, Bataillon G, Portelance L, Golmard L, Meunier L, Tonin PN, Gotlieb W, Yasmeen A, Ray-Coquard I, Labidi-Galy SI, et al. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecologic Oncology. PMID 31753525 DOI: 10.1016/J.Ygyno.2019.11.019 |
0.48 |
|
| 2019 |
Glentis S, Dimopoulos AC, Rouskas K, Ntritsos G, Evangelou E, Narod SA, Mes-Masson AM, Foulkes WD, Rivera B, Tonin PN, Ragoussis J, Dimas AS. Exome Sequencing in and -Negative Greek Families Identifies and as Candidate Risk Genes for Hereditary Breast Cancer. Frontiers in Genetics. 10: 1005. PMID 31681433 DOI: 10.3389/Fgene.2019.01005 |
0.471 |
|
| 2019 |
Octeau D, Kessous R, Klein K, Kogan L, Pelmus M, Ferenczy A, Greenwood CM, Van Kempen LC, Salvador S, Lau S, Tonin PN, Yasmeen A, Gotlieb WH. Outcome-Related Differences in Gene Expression Profiles of High Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. Molecular Cancer Research : McR. PMID 31530633 DOI: 10.1158/1541-7786.Mcr-19-0398 |
0.445 |
|
| 2018 |
Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, et al. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. Bmc Cancer. 18: 347. PMID 29587661 DOI: 10.1186/S12885-018-4242-8 |
0.326 |
|
| 2018 |
Kessous R, Octeau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, Gotlieb WH. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Gynecologic Oncology. PMID 29395310 DOI: 10.1016/J.Ygyno.2018.01.017 |
0.444 |
|
| 2018 |
Kessous R, Octeau D, Kogan L, Tonin P, Laskov I, Klein K, Salvador S, Lau S, Yasmeen A, Gotlieb WH. Homologous recombination pathway mutations in freshly isolated tumor cells from patients with ovarian cancer correlate with outcome Gynecologic Oncology. 149: 167-168. DOI: 10.1016/J.Ygyno.2018.04.383 |
0.455 |
|
| 2017 |
Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, ... ... Tonin PN, et al. Functionally null RAD51D missense mutation associates strongly with ovarian carcinoma. Cancer Research. PMID 28646019 DOI: 10.1158/0008-5472.Can-17-0190 |
0.45 |
|
| 2017 |
Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, ... ... Tonin PN, et al. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Research. PMID 28254861 DOI: 10.1158/0008-5472.Can-16-2179 |
0.488 |
|
| 2017 |
Alenezi WM, Revil T, Badescu D, Arcand SL, Rouleau G, Ragoussis I, Tonin PN. Abstract A25: Investigating the co-occurrence of potentially pathogenic DNA repair pathways alleles in BRCA1 or BRCA2 mutation carrier women with ovarian cancer. Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-A25 |
0.492 |
|
| 2017 |
Rivera B, Iorio MRD, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk D, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, ... ... Tonin PN, et al. Abstract 2479: A functionally nullRAD51Dmissense mutation is strongly associated with ovarian carcinoma Cancer Research. 77: 2479-2479. DOI: 10.1158/1538-7445.Am2017-2479 |
0.348 |
|
| 2016 |
Oros Klein K, Oualkacha K, Lafond MH, Bhatnagar S, Tonin PN, Greenwood CM. Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations. Frontiers in Genetics. 7: 137. PMID 27536319 DOI: 10.3389/Fgene.2016.00137 |
0.507 |
|
| 2016 |
Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, Provencher D, Mes-Masson AM. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines. Oncotarget. PMID 27374179 DOI: 10.18632/Oncotarget.10308 |
0.401 |
|
| 2016 |
Al-Habyan S, Szymborski J, Tonin P, McCaffrey L. Abstract B54: Single and collective cell dissemination modes in ovarian cancer. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B54 |
0.449 |
|
| 2015 |
Fleury H, Communal L, Carmona E, Portelance L, Arcand SL, Rahimi K, Tonin PN, Provencher D, Mes-Masson AM. Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes & Cancer. 6: 378-98. PMID 26622941 DOI: 10.18632/Genesandcancer.76 |
0.496 |
|
| 2015 |
Légaré S, Cavallone L, Mamo A, Chabot C, Sirois I, Magliocco A, Klimowicz A, Tonin PN, Buchanan M, Keilty D, Hassan S, Laperrière D, Mader S, Aleynikova O, Basik M. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers. Cancer Research. 75: 4351-63. PMID 26297734 DOI: 10.1158/0008-5472.Can-14-3475 |
0.458 |
|
| 2015 |
Ancot F, Arcand SL, Mes-Masson AM, Provencher DM, Tonin PN. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. Oncology Letters. 9: 2787-2790. PMID 26137147 DOI: 10.3892/Ol.2015.3123 |
0.489 |
|
| 2015 |
Arcand SL, Akbari MR, Mes-Masson AM, Provencher D, Foulkes WD, Narod SA, Tonin PN. Germline TP53 mutational spectrum in French Canadians with breast cancer. Bmc Medical Genetics. 16: 24. PMID 25925845 DOI: 10.1186/S12881-015-0169-Y |
0.48 |
|
| 2015 |
Cybulski C, Carrot-Zhang J, Klu?niak W, Rivera B, Kashyap A, Woko?orczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, ... ... Tonin PN, et al. Germline RECQL mutations are associated with breast cancer susceptibility. Nature Genetics. 47: 643-6. PMID 25915596 DOI: 10.1038/Ng.3284 |
0.327 |
|
| 2015 |
Gambaro K, Quinn MC, Cáceres-Gorriti KY, Shapiro RS, Provencher D, Rahimi K, Mes-Masson AM, Tonin PN. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome. Bmc Cancer. 15: 135. PMID 25886299 DOI: 10.1186/S12885-015-1138-8 |
0.468 |
|
| 2015 |
Belanger MH, Dolman L, Arcand SL, Shen Z, Chong G, Mes-Masson AM, Provencher D, Tonin PN. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population. Journal of Ovarian Research. 8: 1. PMID 25884701 DOI: 10.1186/S13048-015-0124-8 |
0.439 |
|
| 2015 |
AlShehri E, Belanger M, Arcand S, Oros KK, Greenwood C, Tonin PN. Abstract POSTER-TECH-1101: Characterization of genomic landscapes of BRCA1 and BRCA2 implicated ovarian cancer specimens from a founder french canadian population Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Tech-1101 |
0.509 |
|
| 2014 |
Cáceres-Gorriti KY, Carmona E, Barrès V, Rahimi K, Létourneau IJ, Tonin PN, Provencher D, Mes-Masson AM. RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer. Plos One. 9: e91000. PMID 24625450 DOI: 10.1371/Journal.Pone.0091000 |
0.433 |
|
| 2014 |
Joly Y, Tonin PN. Social, ethical and legal considerations raised by the discovery and patenting of the BRCA1 and BRCA2 genes New Genetics and Society. 33: 167-180. DOI: 10.1080/14636778.2014.914849 |
0.462 |
|
| 2013 |
Oros KK, Arcand SL, Bayani J, Squire JA, Mes-Masson AM, Tonin PN, Greenwood CM. Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance. Cancer Genetics. 206: 103-15. PMID 23623180 DOI: 10.1016/J.Cancergen.2013.03.001 |
0.365 |
|
| 2013 |
Gamwell LF, Gambaro K, Merziotis M, Crane C, Arcand SL, Bourada V, Davis C, Squire JA, Huntsman DG, Tonin PN, Vanderhyden BC. Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet Journal of Rare Diseases. 8: 33. PMID 23433318 DOI: 10.1186/1750-1172-8-33 |
0.444 |
|
| 2013 |
Gambaro K, Quinn MC, Wojnarowicz PM, Arcand SL, de Ladurantaye M, Barrès V, Ripeau JS, Killary AM, Davis EC, Lavoie J, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN. VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer. Molecular Oncology. 7: 513-30. PMID 23415753 DOI: 10.1016/J.Molonc.2012.12.006 |
0.542 |
|
| 2013 |
Quinn MC, Wojnarowicz PM, Pickett A, Provencher DM, Mes-Masson AM, Davis EC, Tonin PN. FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. International Journal of Oncology. 42: 912-20. PMID 23354471 DOI: 10.3892/Ijo.2013.1797 |
0.476 |
|
| 2013 |
Tischkowitz M, Sabbaghian N, Hamel N, Pouchet C, Foulkes WD, Mes-Masson AM, Provencher DM, Tonin PN. Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. Bmc Medical Genetics. 14: 5. PMID 23302520 DOI: 10.1186/1471-2350-14-5 |
0.477 |
|
| 2013 |
Guidugli L, Pankratz VS, Singh N, Thompson J, Erding CA, Engel C, Schmutzler R, Domchek S, Nathanson K, Radice P, Singer C, Tonin PN, Lindor NM, Goldgar DE, Couch FJ. A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. Cancer Research. 73: 265-75. PMID 23108138 DOI: 10.1158/0008-5472.Can-12-2081 |
0.4 |
|
| 2013 |
Légaré S, Cavallone L, Mamo A, Chabot C, Keilty D, Magliocco A, Klimowicz A, Tonin P, Basik M. Abstract LB-47: SPEN is a novel candidate tumor suppressor gene that regulates response to tamoxifen in estrogen receptor positive breast cancers. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-47 |
0.497 |
|
| 2013 |
Tonin PN, Greenwood CM, Provencher DM, Mes-Masson A. Abstract B24: Using a unique genetically modified ovarian cancer cell line model to identify the targets for siRNA directed therapies Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B24 |
0.486 |
|
| 2012 |
Wojnarowicz P, Gambaro K, de Ladurantaye M, Quinn MC, Provencher D, Mes-Masson AM, Tonin PN. Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity. Oncogenesis. 1: e27. PMID 23552840 DOI: 10.1038/oncsis.2012.25 |
0.436 |
|
| 2012 |
Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, Madore J, Birch AH, de Ladurantaye M, Rahimi K, Provencher DM, Mes-Masson AM, Greenwood CM, Tonin PN. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. Plos One. 7: e45484. PMID 23029043 DOI: 10.1371/Journal.Pone.0045484 |
0.405 |
|
| 2012 |
Létourneau IJ, Quinn MCJ, Wang LL, Portelance L, Caceres KY, Cyr L, Delvoye N, Meunier L, de Ladurantaye M, Shen Z, Arcand SL, Tonin PN, Provencher DM, Mes-Masson AM. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer Bmc Cancer. 12. PMID 22931248 DOI: 10.1186/1471-2407-12-379 |
0.442 |
|
| 2012 |
Osher DJ, Leeneer KD, Michils G, Hamel N, Tomiak E, Poppe B, Leunen K, Legius E, Shuen A, Smith E, Arseneau J, Tonin P, Matthijs G, Claes K, Tischkowitz MD, et al. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. British Journal of Cancer. 106: 1460-1463. PMID 22415235 DOI: 10.1038/Bjc.2012.87 |
0.501 |
|
| 2012 |
Abd-Rabbo D, Abaji C, Cardin GB, Filali-Mouhim A, Arous C, Portelance L, Escobar E, Cloutier S, Tonin PN, Provencher DM, Mes-Masson AM, Maugard CM. Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation. Cancer Prevention Research (Philadelphia, Pa.). 5: 765-77. PMID 22401979 DOI: 10.1158/1940-6207.Capr-11-0547 |
0.475 |
|
| 2012 |
Wojnarowicz PM, Provencher DM, Mes-Masson AM, Tonin PN. Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. International Journal of Oncology. 40: 1865-80. PMID 22344671 DOI: 10.3892/Ijo.2012.1371 |
0.529 |
|
| 2012 |
Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson AM, Ghadirian P, Foulkes WD, Tischkowitz M, Narod SA, Provencher D, Tonin PN. The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. Breast Cancer Research and Treatment. 131: 333-40. PMID 21947752 DOI: 10.1007/S10549-011-1796-4 |
0.472 |
|
| 2012 |
Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E, Malcolm K, Mousses S, Tonin PN, Basik M. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene. 31: 2090-100. PMID 21892209 DOI: 10.1038/Onc.2011.386 |
0.524 |
|
| 2011 |
Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, Greenwood CM, Mes-Masson AM, Tonin PN. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. Plos One. 6: e28250. PMID 22163003 DOI: 10.1371/Journal.Pone.0028250 |
0.453 |
|
| 2011 |
Chabot C, Mamo A, Cavallone L, Tuzmen S, Hassan S, Edgren H, Ferrario C, Aleynikova O, Przybytkowska E, Malcolm K, Kallioniemi O, Tonin P, Mousses S, Basik M. Abstract 4023: ARID1A is a candidate tumor suppressor gene in breast cancer Cellular and Molecular Biology. 71: 4023-4023. DOI: 10.1158/1538-7445.Am2011-4023 |
0.454 |
|
| 2011 |
Wojnarowicz PM, Gambaro K, Desaulniers KL, Ladurantaye Md, Provencher D, Mes-Masson A, Tonin PN. Abstract 3059: CCL2 overexpression in an epithelial ovarian cancer cell line results in reduced tumorigenic potential Cancer Research. 71: 3059-3059. DOI: 10.1158/1538-7445.Am2011-3059 |
0.524 |
|
| 2010 |
Barrès V, Ouellet V, Lafontaine J, Tonin PN, Provencher DM, Mes-Masson AM. An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Molecular Cancer. 9: 272. PMID 20942967 DOI: 10.1186/1476-4598-9-272 |
0.474 |
|
| 2010 |
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, ... ... Tonin PN, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. The New England Journal of Medicine. 363: 1532-43. PMID 20942669 DOI: 10.1056/Nejmoa1008433 |
0.438 |
|
| 2010 |
Akbari MR, Tonin P, Foulkes WD, Ghadirian P, Tischkowitz M, Narod SA. RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Research : Bcr. 12: 404. PMID 20723205 DOI: 10.1186/Bcr2619 |
0.473 |
|
| 2010 |
Cavallone L, Arcand SL, Maugard CM, Nolet S, Gaboury LA, Mes-Masson AM, Ghadirian P, Provencher D, Tonin PN. Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Familial Cancer. 9: 507-17. PMID 20694749 DOI: 10.1007/S10689-010-9372-3 |
0.446 |
|
| 2010 |
Meunier L, Puiffe ML, Le Page C, Filali-Mouhim A, Chevrette M, Tonin PN, Provencher DM, Mes-Masson AM. Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. Translational Oncology. 3: 230-8. PMID 20689764 DOI: 10.1593/Tlo.10103 |
0.519 |
|
| 2010 |
Hosein AN, Wu M, Arcand SL, Lavallée S, Hébert J, Tonin PN, Basik M. Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Research. 70: 5770-7. PMID 20570891 DOI: 10.1158/0008-5472.Can-10-0673 |
0.511 |
|
| 2010 |
Normandin K, Péant B, Le Page C, de Ladurantaye M, Ouellet V, Tonin PN, Provencher DM, Mes-Masson AM. Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. Clinical & Experimental Metastasis. 27: 55-69. PMID 20049513 DOI: 10.1007/S10585-009-9303-6 |
0.464 |
|
| 2010 |
Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. The Journal of Pathology. 220: 392-400. PMID 19967725 DOI: 10.1002/Path.2659 |
0.361 |
|
| 2009 |
Quinn MC, Wilson DJ, Young F, Dempsey AA, Arcand SL, Birch AH, Wojnarowicz PM, Provencher D, Mes-Masson AM, Englert D, Tonin PN. The chemiluminescence based Ziplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles. Journal of Translational Medicine. 7: 55. PMID 19580657 DOI: 10.1186/1479-5876-7-55 |
0.426 |
|
| 2009 |
Manderson EN, Birch AH, Shen Z, Mes-Masson AM, Provencher D, Tonin PN. Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer International Journal of Gynecological Cancer. 19: 513-525. PMID 19509545 DOI: 10.1111/Igc.0B013E3181A3Cd38 |
0.817 |
|
| 2009 |
Tonin PN. Thematic issue on the molecular biology of hereditary ovarian cancer. Preface. Molecular Oncology. 3: 94-6. PMID 19383373 DOI: 10.1016/J.Molonc.2009.02.002 |
0.44 |
|
| 2009 |
Le Page C, Puiffe ML, Meunier L, Zietarska M, de Ladurantaye M, Tonin PN, Provencher D, Mes-Masson AM. BMP-2 signaling in ovarian cancer and its association with poor prognosis. Journal of Ovarian Research. 2: 4. PMID 19366455 DOI: 10.1186/1757-2215-2-4 |
0.502 |
|
| 2009 |
Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN. Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Molecular Carcinogenesis. 48: 1077-92. PMID 19347865 DOI: 10.1002/Mc.20535 |
0.54 |
|
| 2009 |
Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN. Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Molecular Carcinogenesis. 48: 648-61. PMID 19123201 DOI: 10.1002/Mc.20511 |
0.57 |
|
| 2008 |
Ouellet V, Ling TH, Normandin K, Madore J, Lussier C, Barrès V, Bachvarov D, Rancourt C, Tonin PN, Provencher DM, Mes-Masson AM. Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. Bmc Cancer. 8: 346. PMID 19032793 DOI: 10.1186/1471-2407-8-346 |
0.323 |
|
| 2008 |
Novak DJ, Chen LQ, Ghadirian P, Hamel N, Zhang P, Rossiny V, Cardinal G, Robidoux A, Tonin PN, Rousseau F, Narod SA, Foulkes WD. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women. Bmc Cancer. 8: 239. PMID 18706089 DOI: 10.1186/1471-2407-8-239 |
0.434 |
|
| 2008 |
Cody NA, Zietarska M, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN. Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines. Bmc Medical Genomics. 1: 34. PMID 18687136 DOI: 10.1186/1755-8794-1-34 |
0.504 |
|
| 2008 |
Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, Puiffe ML, Arcand SL, Shen Z, Hébert J, Tonin PN, Provencher DM, Mes-Masson AM. Characterization of three new serous epithelial ovarian cancer cell lines. Bmc Cancer. 8: 152. PMID 18507860 DOI: 10.1186/1471-2407-8-152 |
0.487 |
|
| 2008 |
Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. Bmc Cancer. 8: 96. PMID 18402691 DOI: 10.1186/1471-2407-8-96 |
0.451 |
|
| 2008 |
Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, Mes-Masson AM. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 913-20. PMID 18398031 DOI: 10.1158/1055-9965.Epi-07-0692 |
0.446 |
|
| 2008 |
Wojnarowicz PM, Breznan A, Arcand SL, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN. Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 18: 963-75. PMID 18028382 DOI: 10.1111/J.1525-1438.2007.01134.X |
0.467 |
|
| 2008 |
Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN. Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Molecular Carcinogenesis. 47: 56-65. PMID 17620309 DOI: 10.1002/Mc.20361 |
0.517 |
|
| 2008 |
Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, Fafard E, Mes-Masson AM, Foulkes WD, Provencher D, Narod SA, Tonin PN. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Research and Treatment. 108: 399-408. PMID 17541742 DOI: 10.1007/S10549-007-9608-6 |
0.445 |
|
| 2007 |
Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia (New York, N.Y.). 9: 820-9. PMID 17971902 DOI: 10.1593/Neo.07472 |
0.537 |
|
| 2007 |
Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Familial Cancer. 6: 491-7. PMID 17636423 DOI: 10.1007/S10689-007-9152-X |
0.49 |
|
| 2007 |
Ouellet V, Le Page C, Madore J, Guyot MC, Barrès V, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM. An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer. Cancer. 110: 297-308. PMID 17569106 DOI: 10.1002/Cncr.22812 |
0.416 |
|
| 2007 |
Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, Mes-Masson AM. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Molecular Carcinogenesis. 46: 872-85. PMID 17455221 DOI: 10.1002/Mc.20315 |
0.48 |
|
| 2007 |
Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, ... ... Tonin PN, et al. Analysis of PALB2/FANCN-associated breast cancer families. Proceedings of the National Academy of Sciences of the United States of America. 104: 6788-93. PMID 17420451 DOI: 10.1073/Pnas.0701724104 |
0.498 |
|
| 2007 |
Benoît MH, Hudson TJ, Maire G, Squire JA, Arcand SL, Provencher D, Mes-Masson AM, Tonin PN. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. International Journal of Oncology. 30: 5-17. PMID 17143508 DOI: 10.3892/Ijo.30.1.5 |
0.487 |
|
| 2007 |
Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, Tellis P, Zietarska M, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene. 26: 618-32. PMID 16909122 DOI: 10.1038/Sj.Onc.1209821 |
0.808 |
|
| 2006 |
Tonin PN. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]. Bulletin Du Cancer. 93: 841-6. PMID 16980226 |
0.385 |
|
| 2006 |
Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin PN. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Clinical Genetics. 70: 320-9. PMID 16965326 DOI: 10.1111/j.1399-0004.2006.00673.x |
0.334 |
|
| 2006 |
Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM. SET complex in serous epithelial ovarian cancer. International Journal of Cancer. 119: 2119-26. PMID 16823850 DOI: 10.1002/Ijc.22054 |
0.431 |
|
| 2006 |
Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. International Journal of Cancer. 119: 599-607. PMID 16572426 DOI: 10.1002/Ijc.21902 |
0.438 |
|
| 2006 |
Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, Foulkes WD, Ghadirian P, Provencher D, Tonin PN. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. Bmc Medical Genetics. 7: 23. PMID 16539696 DOI: 10.1186/1471-2350-7-23 |
0.473 |
|
| 2006 |
Le Page C, Quellet V, Madore J, Ren F, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM. Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer British Journal of Cancer. 94: 436-445. PMID 16421595 DOI: 10.1038/Sj.Bjc.6602933 |
0.468 |
|
| 2006 |
Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer International Journal of Cancer. 118: 1750-1758. PMID 16217764 DOI: 10.1002/Ijc.21521 |
0.405 |
|
| 2005 |
Arcand SL, Provencher D, Mes-Masson AM, Tonin PN. OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer. International Journal of Oncology. 27: 1315-20. PMID 16211227 DOI: 10.3892/Ijo.27.5.1315 |
0.462 |
|
| 2005 |
Foulkes WD, Hamel N, Oros KK, Tonin PN. BRCA mutations and ductal carcinoma in situ. Jama. 294: 553-4. PMID 16077047 DOI: 10.1001/Jama.294.5.553 |
0.337 |
|
| 2005 |
Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson AM. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene. 24: 4672-87. PMID 15940270 DOI: 10.1038/Sj.Onc.1208214 |
0.429 |
|
| 2005 |
Presneau N, Dewar K, Forgetta V, Provencher D, Mes-Masson AM, Tonin PN. Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Molecular Carcinogenesis. 43: 141-54. PMID 15937959 DOI: 10.1002/Mc.20096 |
0.45 |
|
| 2005 |
Presneau N, Shen Z, Provencher D, Mes-Masson AM, Tonin PN. Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. International Journal of Oncology. 26: 1621-7. PMID 15870878 DOI: 10.3892/Ijo.26.6.1621 |
0.468 |
|
| 2005 |
Ghadirian P, Lubinski J, Lynch HT, Neuhausen SL, Weber B, Isaacs C, Baruch RG, Randall S, Ainsworth P, Freidman E, Horsman D, Tonin P, Foulkes WD, Tung N, Sun P, et al. Erratum: Smoking and the risk of breast cancer among carriers of BRCA mutations (International Journal of Cancer (2004) 110 (413-416)) International Journal of Cancer. 114. DOI: 10.1002/Ijc/20752 |
0.433 |
|
| 2004 |
Oros KK, Ghadirian P, Greenwood CM, Perret C, Shen Z, Paredes Y, Arcand SL, Mes-Masson AM, Narod SA, Foulkes WD, Provencher D, Tonin PN. Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. International Journal of Cancer. Journal International Du Cancer. 112: 411-9. PMID 15382066 DOI: 10.1002/Ijc.20406 |
0.423 |
|
| 2004 |
Arcand SL, Mes-Masson AM, Provencher D, Hudson TJ, Tonin PN. Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region Molecular Carcinogenesis. 41: 17-38. PMID 15352123 DOI: 10.1002/Mc.20038 |
0.44 |
|
| 2004 |
Samouëlian V, Maugard CM, Jolicoeur M, Bertrand R, Arcand SL, Tonin PN, Provencher DM, Mes-Masson AM. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemotherapy and Pharmacology. 54: 497-504. PMID 15258697 DOI: 10.1007/S00280-004-0843-9 |
0.465 |
|
| 2004 |
Ghadirian P, Lubinski J, Lynch H, Neuhausen SL, Weber B, Isaacs C, Baruch RG, Randall S, Ainsworth P, Friedman E, Freidman E, Horsman D, Tonin P, Foulkes WD, Tung N, et al. Smoking and the risk of breast cancer among carriers of BRCA mutations. International Journal of Cancer. Journal International Du Cancer. 110: 413-6. PMID 15095307 DOI: 10.1002/Ijc.20106 |
0.391 |
|
| 2004 |
Tonin PN. Molecular Analysis of Cancer, by J. Boultwood and C. Fidler American Journal of Medical Genetics Part A. 124: 329-330. DOI: 10.1002/Ajmg.A.20301 |
0.375 |
|
| 2003 |
Presneau N, Manderson EN, Tonin PN. The quest for a tumor suppressor gene phenotype. Current Molecular Medicine. 3: 605-29. PMID 14601636 DOI: 10.2174/1566524033479500 |
0.788 |
|
| 2003 |
Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, Tonin PN. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines Oncogene. 22: 1568-1579. PMID 12629520 DOI: 10.1038/Sj.Onc.1206219 |
0.496 |
|
| 2002 |
Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. Journal of Medical Genetics. 39: 608-10. PMID 12161606 DOI: 10.1136/Jmg.39.8.608 |
0.442 |
|
| 2002 |
Manderson EN, Presneau N, Provencher D, Mes-Masson AM, Tonin PN. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. Molecular Carcinogenesis. 34: 78-90. PMID 12112314 DOI: 10.1002/Mc.10051 |
0.789 |
|
| 2002 |
Laaziri K, Sutton M, Ghadirian P, Scott AS, Paradis AJ, Tonin PN, Foulkes WD. Is there a correlation between the structure of hair and breast cancer or BRCA1/2 mutations? Physics in Medicine and Biology. 47: 1623-32. PMID 12069082 DOI: 10.1088/0031-9155/47/10/301 |
0.452 |
|
| 2002 |
Manderson EN, Mes-Masson AM, Novak J, Lee PD, Provencher D, Hudson TJ, Tonin PN. Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Research. 12: 112-21. PMID 11779836 DOI: 10.1101/Gr.174202 |
0.783 |
|
| 2001 |
Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B, ... ... Tonin P, et al. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 11: 635-8. PMID 11668223 DOI: 10.1097/00008571-200110000-00010 |
0.486 |
|
| 2001 |
Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, Manderson EN, Provencher D, Mes-Masson AM. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene. 20: 6617-26. PMID 11641787 DOI: 10.1038/Sj.Onc.1204804 |
0.795 |
|
| 2001 |
Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, Peretz T, Narod SA, Mes-Masson AM, Foulkes WD, Wang T, Morgan K, Fujiwara TM, Tonin PN. Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families Human Heredity. 52: 116-120. PMID 11512557 DOI: 10.1159/000053364 |
0.43 |
|
| 2001 |
Chappuis PO, Hamel N, Paradis AJ, Deschênes J, Robidoux A, Potvin C, Cantin J, Tonin P, Ghadirian P, Foulkes WD. Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer Clinical Genetics. 59: 418-423. PMID 11453973 DOI: 10.1034/j.1399-0004.2001.590606.x |
0.307 |
|
| 2001 |
Khittoo G, Manning A, Mustun H, Appadoo J, Venkatasamy S, Fagoonee I, Ghadirian P, Tonin PN. Mutation analysis of a Mauritian hereditary breast cancer family reveals the BRCA2 6503deITT mutation previously found to recur in different ethnic populations. Human Heredity. 52: 55-8. PMID 11359068 DOI: 10.1159/000053354 |
0.4 |
|
| 2001 |
Tonin PN, Perret C, Lambert JA, Paradis AJ, Kantemiroff T, Benoît MH, Martin G, Foulkes WD, Ghadirian P. Founder BRCA1 and BRCA2 mutations in early-onset french Canadian breast cancer cases unselected for family history International Journal of Cancer. 95: 189-193. PMID 11307153 DOI: 10.1002/1097-0215(20010520)95:3<189::Aid-Ijc1032>3.0.Co;2-N |
0.484 |
|
| 2001 |
Chappuis PO, Hamel N, Paradis AJ, Deschênes J, Tonin PN, Ghadirian P, Foulkes WD. Re: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected finnish breast cancer patients (multiple letters) [2] Journal of the National Cancer Institute. 93: 152-154. PMID 11208888 DOI: 10.1093/Jnci/93.2.152-A |
0.428 |
|
| 2001 |
Vattemi G, Tonin P, Martignoni G, Filosto M, Marchioretto F, Rizzuto N, Tomelleri G. Dermatomyositis and retroperitoneal germ cell cancer. European Neurology. 45: 52-3. PMID 11150842 DOI: 10.1159/000052090 |
0.354 |
|
| 2000 |
Singh R, Eeles RA, Durocher F, Simard J, Edwards S, Badzioch M, Kote-Jarai Z, Teare D, Ford D, Dearnaley D, Ardern-Jones A, Murkin A, Dowe A, Shearer R, Kelly J, ... ... Tonin PN, et al. High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer and Prostatic Diseases. 3: 241-247. PMID 12497071 DOI: 10.1038/Sj.Pcan.4500478 |
0.383 |
|
| 2000 |
Provencher DM, Lounis H, Champoux L, Tétrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN, Mes-Masson AM. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cellular & Developmental Biology. Animal. 36: 357-61. PMID 10949993 DOI: 10.1290/1071-2690(2000)036<0357:Cofneo>2.0.Co;2 |
0.792 |
|
| 2000 |
Tonin PN. Genes implicated in hereditary breast cancer syndromes. Seminars in Surgical Oncology. 18: 281-6. PMID 10805949 DOI: 10.1002/(SICI)1098-2388(200006)18:4<281::AID-SSU2>3.0.CO;2-Q |
0.38 |
|
| 2000 |
Manderson EN, Mes-Masson AM, Provencher D, Tonin PN. Mutations in a 10-bp polyadenine repeat of transforming growth factor beta-receptor type II gene is an infrequent event in human epithelial ovarian cancer. Clinical Genetics. 57: 151-3. PMID 10735638 |
0.774 |
|
| 2000 |
Wang J, Mes-Masson AM, Tonin PN, Provencher D, Eydoux P. Trisomy of chromosome 10 in two cases of ovarian carcinoma. Cancer Genetics and Cytogenetics. 118: 65-8. PMID 10731594 DOI: 10.1016/S0165-4608(99)00170-3 |
0.39 |
|
| 1999 |
Hamel N, Manning A, Black MJ, Tonin PN, Foulkes WD. An absence of founder BRCA2 mutations in individuals with squamous cell carcinoma of the head and neck. International Journal of Cancer. 83: 803-4. PMID 10597198 DOI: 10.1002/(Sici)1097-0215(19991210)83:6<803::Aid-Ijc17>3.0.Co;2-N |
0.327 |
|
| 1999 |
Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P, Provencher D. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clinical Genetics. 55: 318-24. PMID 10422801 DOI: 10.1034/J.1399-0004.1999.550504.X |
0.511 |
|
| 1999 |
Manning AP, Mes-Masson AM, Seymour RJ, Tetrault M, Provencher DM, Tonin PN. Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites. Molecular Carcinogenesis. 24: 218-25. PMID 10204806 DOI: 10.1002/(Sici)1098-2744(199903)24:3<218::Aid-Mc8>3.0.Co;2-A |
0.51 |
|
| 1998 |
Rahman N, Abidi F, Ford D, Arbour L, Rapley E, Tonin P, Barton D, Batcup G, Berry J, Cotter F, Davison V, Gerrard M, Gray E, Grundy R, Hanafy M, et al. Confirmation of FWT1 as a Wilms' tumour susceptibility gene and phenotypic characteristics of Wilms' tumour attributable to FWT1 Human Genetics. 103: 547-556. PMID 9860296 DOI: 10.1007/Pl00008708 |
0.348 |
|
| 1998 |
Lounis H, Mes-Masson AM, Dion F, Bradley WE, Seymour RJ, Provencher D, Tonin PN. Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene. 17: 2359-65. PMID 9811467 DOI: 10.1038/Sj.Onc.1202152 |
0.459 |
|
| 1998 |
Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. American Journal of Human Genetics. 63: 1341-51. PMID 9792861 DOI: 10.1086/302099 |
0.464 |
|
| 1998 |
Dong J, Chang-Claude J, Wu Y, Schumacher V, Debatin I, Tonin P, Royer-Pokora B. A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3′ third of the gene Human Genetics. 103: 154-161. PMID 9760198 DOI: 10.1007/S004390050799 |
0.462 |
|
| 1998 |
Godard B, Foulkes WD, Provencher D, Brunet JS, Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P. Risk factors for familial and sporadic ovarian cancer among French Canadians: A case-control study American Journal of Obstetrics and Gynecology. 179: 403-410. PMID 9731846 DOI: 10.1016/S0002-9378(98)70372-2 |
0.417 |
|
| 1998 |
Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin PN, Abrahamson J, Foulkes WD, Daly M, Wagner-Costalas J, Godwin A, Olopade OI, Moslehi R, Liede A, Futreal PA, et al. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. Journal of the National Cancer Institute. 90: 761-6. PMID 9605646 DOI: 10.1093/Jnci/90.10.761 |
0.402 |
|
| 1998 |
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, ... ... Tonin P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. American Journal of Human Genetics. 62: 676-89. PMID 9497246 DOI: 10.1086/301749 |
0.455 |
|
| 1998 |
Liede A, Tonin PN, Sun CC, Serruya C, Daly MB, Narod SA, Foulkes WD. Is hereditary site-specific ovarian cancer a distinct genetic condition? American Journal of Medical Genetics. 75: 55-8. PMID 9450858 DOI: 10.1002/(Sici)1096-8628(19980106)75:1<55::Aid-Ajmg12>3.0.Co;2-R |
0.503 |
|
| 1997 |
Foulkes WD, Wong N, Brunet JS, Bégin LR, Zhang JC, Martinez JJ, Rozen F, Tonin PN, Narod SA, Karp SE, Pollak MN. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 3: 2465-9. PMID 9815648 |
0.333 |
|
| 1997 |
Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Research and Treatment. 44: 275-7. PMID 9266108 DOI: 10.1023/A:1005830230664 |
0.421 |
|
| 1997 |
Karp SE, Tonin PN, Bégin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 80: 435-41. PMID 9241077 DOI: 10.1002/(Sici)1097-0142(19970801)80:3<435::Aid-Cncr11>3.0.Co;2-Y |
0.42 |
|
| 1997 |
Rahman N, Arbour L, Tonin P, Baruchel S, Pritchard-Jones K, Narod SA, Stratton MR. The familial Wilms' tumour susceptibility gene, FWT1, may not be a tumour suppressor gene. Oncogene. 14: 3099-102. PMID 9223674 DOI: 10.1038/Sj.Onc.1201107 |
0.433 |
|
| 1997 |
Lynch HT, Lemon SJ, Durham C, Tinley ST, Connolly C, Lynch JF, Surdam J, Orinion E, Slominski-Caster S, Watson P, Lerman C, Tonin P, Lenoir G, Serova O, Narod S. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 79: 2219-28. PMID 9179070 DOI: 10.1002/(Sici)1097-0142(19970601)79:11<2219::Aid-Cncr21>3.0.Co;2-Y |
0.329 |
|
| 1997 |
Brunet JS, Narod SA, Tonin P, Foulkes WD. BRCA1 mutations and survival in women with ovarian cancer. The New England Journal of Medicine. 336: 1256; author reply 1. PMID 9121524 |
0.319 |
|
| 1997 |
Cannistra SA, Whittmore SE, Burk RD, Modan B, Johannsson OT, Ranstam J, Borg A, Olsson H, Brunet JS, Narod SA, Tonin P, Foulkes WD, Rubin SC. BRCA1 mutations and survival in women with ovarian cancer. The New England Journal of Medicine. 336: 1254-1257. PMID 9121519 DOI: 10.1056/Nejm199704243361713 |
0.429 |
|
| 1997 |
Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM. Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancer-susceptibility genes? American Journal of Human Genetics. 60: 486-495. PMID 9042907 |
0.358 |
|
| 1996 |
Durocher F, Tonin P, Shattuck-Eidens D, Skolnick M, Narod SA, Simard J. Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. Journal of Medical Genetics. 33: 814-9. PMID 8933332 DOI: 10.1136/Jmg.33.10.814 |
0.491 |
|
| 1996 |
Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families Nature Medicine. 2: 1179-1183. PMID 8898735 DOI: 10.1038/Nm1196-1179 |
0.455 |
|
| 1996 |
Foulkes WD, Bolduc N, Lambert D, Ginsburg O, Olien L, Yandell DW, Tonin PN, Narod SA. Increased incidence of cancer in first degree relatives of women with double primary carcinomas of the breast and colon. Journal of Medical Genetics. 33: 534-9. PMID 8818936 DOI: 10.1136/Jmg.33.7.534 |
0.444 |
|
| 1996 |
Rahman N, Arbour L, Tonin P, Renshaw J, Pelletier J, Baruchel S, Pritchard-Jones K, Stratton MR, Narod SA. Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. Nature Genetics. 13: 461-3. PMID 8696342 DOI: 10.1038/Ng0896-461 |
0.424 |
|
| 1996 |
Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher MC, Dole K, Karimi S, Foulkes W, Lounis H, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genetics. 13: 120-2. PMID 8673090 DOI: 10.1038/Ng0596-120 |
0.474 |
|
| 1996 |
Phelan CM, Larsson C, Baird S, Futreal PA, Ruttledge MH, Morgan K, Tonin P, Hung H, Korneluk RG, Pollak MN, Narod SA. The human mammary-derived growth inhibitor (MDGI) gene: Genomic structure and mutation analysis in human breast tumors Genomics. 34: 63-68. PMID 8661024 DOI: 10.1006/Geno.1996.0241 |
0.506 |
|
| 1996 |
Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes Journal of the American Medical Association. 275: 1885-1892. PMID 8648868 DOI: 10.1001/Jama.275.24.1885 |
0.393 |
|
| 1996 |
Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 77: 697-709. PMID 8616762 DOI: 10.1002/(Sici)1097-0142(19960215)77:4<697::Aid-Cncr16>3.0.Co;2-W |
0.448 |
|
| 1996 |
Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, et al. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. American Journal of Human Genetics. 58: 271-80. PMID 8571953 |
0.346 |
|
| 1996 |
Serova O, Montagna M, Torchard D, Narod SA, Tonin P, Sylla B, Lynch HT, Feunteun J, Lenoir GM. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. American Journal of Human Genetics. 58: 42-51. PMID 8554067 |
0.378 |
|
| 1996 |
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Michlem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, ... ... Tonin P, et al. Identification of the breast cancer susceptibility gene BRCA2 Nature. 379: 749-749. DOI: 10.1038/379749A0 |
0.449 |
|
| 1996 |
Phelan CM, Larsson C, Baird S, Futreal P, Ruttledge M, Morgan K, Tonin P, Hung H, Korneluk RG, Pollak MN, Narod SA. The Human Mammary-Derived Growth Inhibitor (MDGI) Gene: Genomic Structure and Mutation Analysis in Human Breast Tumors Genomics. 36: 377. DOI: 10.1006/Geno.1996.0481 |
0.389 |
|
| 1995 |
Tonin P, Ghadirian P, Phelan C, Lenoir GM, Lynch HT, Letendre F, Belanger D, Monté M, Narod SA. A large multisite cancer family is linked to BRCA2. Journal of Medical Genetics. 32: 982-984. PMID 8825930 DOI: 10.1136/Jmg.32.12.982 |
0.472 |
|
| 1995 |
Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc JF, Bélanger C, Dion F. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genetics. 8: 392-8. PMID 7894492 DOI: 10.1038/Ng1294-392 |
0.489 |
|
| 1995 |
Tonin P, Moslehi R, Green R, Rosen B, Cole D, Boyd N, Cutler C, Margolese R, Carter R, McGillivray B, Ives E, Labrie F, Gilchrist D, Morgan K, Simard J, et al. Linkage analysis of 26 Canadian breast and breast-ovarian cancer families Human Genetics. 95: 545-550. PMID 7759076 DOI: 10.1007/Bf00223867 |
0.5 |
|
| 1995 |
Cornelis RS, Neuhausen SL, Johansson O, Arason A, Kelsell D, Ponder BA, Tonin P, Hamann U, Lindblom A, Lalle P. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes, Chromosomes & Cancer. 13: 203-10. PMID 7669740 DOI: 10.1002/Gcc.2870130310 |
0.469 |
|
| 1995 |
Rommens JM, Durocher F, McArthur J, Tonin P, LeBlanc J, Allen T, Samson C, Ferri L, Narod S, Morgan K, Simard J. Generation of a Transcription Map at the HSD17B Locus Centromeric to BRCA1 at 17q21 Genomics. 28: 530-542. PMID 7490091 DOI: 10.1006/Geno.1995.1185 |
0.376 |
|
| 1995 |
Narod SA, Madlensky L, Bradley L, Cole D, Tonin P, Rosen B, Risch HA. Hereditary and Familial Ovarian Cancer in Southern Ontario Obstetrical & Gynecological Survey. 50: 194-195. DOI: 10.1097/00006254-199503000-00017 |
0.435 |
|
| 1994 |
Green RC, Narod SA, Morasse J, Young TL, Cox J, Fitzgerald GW, Tonin P, Ginsburg O, Miller S, Jothy S. Hereditary nonpolyposis colon cancer: analysis of linkage to 2p15-16 places the COCA1 locus telomeric to D2S123 and reveals genetic heterogeneity in seven Canadian families. American Journal of Human Genetics. 54: 1067-77. PMID 8198129 |
0.319 |
|
| 1994 |
Narod SA, Madlensky L, Bradley L, Cole D, Tonin P, Rosen B, Risch HA. Hereditary and familial ovarian cancer in Southern Ontario Cancer. 74: 2341-2346. PMID 7922985 DOI: 10.1002/1097-0142(19941015)74:8<2341::Aid-Cncr2820740819>3.0.Co;2-Z |
0.484 |
|
| 1994 |
Narod S, Tonin P, Lynch H, Watson P, Feunteun J, Lenoir G. Histology of BRCA1-associated ovarian tumours. Lancet (London, England). 343: 236. PMID 7904689 DOI: 10.1016/S0140-6736(94)91021-9 |
0.356 |
|
| 1994 |
Tonin P, Serova O, Simard J, Lenoir G, Feunteun J, Morgan K, Lynch HT, Narod S. The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12–q21 Human Molecular Genetics. 3: 1679-1682. PMID 7833928 DOI: 10.1093/Hmg/3.9.1679 |
0.519 |
|
| 1994 |
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, ... ... Tonin P, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science. 266: 66-71. PMID 7545954 DOI: 10.1126/Science.7545954 |
0.493 |
|
| 1994 |
Morasse J, Green RC, Narod S, Young T, Tonin P, Morissette J, Weissenbach J, Khandjian EW, Rousseau F. Poster abstractGenetic heterogeneity in hereditary non-polyposis colon cancer as detected with molecular probes Clinical Biochemistry. 27: 200-201. DOI: 10.1016/0009-9120(94)90066-3 |
0.391 |
|
| 1993 |
Simard J, Feunteun J, Lenoir G, Tonin P, Normand T, Luu The V, Vivier A, Lasko D, Morgan K, Rouleau GA. Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA. Human Molecular Genetics. 2: 1193-9. PMID 8401501 DOI: 10.1093/Hmg/2.8.1193 |
0.5 |
|
| 1993 |
Tonin P, Ehrenborg E, Lenoir G, Feunteun J, Lynch H, Morgan K, Zazzi H, Vivier A, Pollak M, Huynh H, Luthman H, Larsson C, Narod S. The Human Insulin-like Growth Factor-Binding Protein 4 Gene Maps to Chromosome Region 17q12-q21.1 and Is Close to the Gene for Hereditary Breast-Ovarian Cancer Genomics. 18: 414-417. PMID 7507078 DOI: 10.1006/Geno.1993.1487 |
0.432 |
|
| 1992 |
Chaudhuri MM, Tonin PN, Lewis WH, Srinivasan PR. The gene for a novel protein, a member of the protein disulphide isomerase/form I phosphoinositide-specific phospholipase C family, is amplified in hydroxyurea-resistant cells. The Biochemical Journal. 281: 645-50. PMID 1311171 DOI: 10.1042/Bj2810645 |
0.313 |
|
| Show low-probability matches. |